01.10.26 -- Bioprocess Online Best Of December

Cyril Konto, CEO at Ichnos Glenmark Innovation, talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,'  and closing a $700 million licensing deal with AbbVie.

Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

When configured correctly, TFF provides the gentle processing environment and oxygen protection required for strict anaerobes.

Discover how solutions driven by artificial intelligence can enhance compliance, optimize workflows, and drive efficiency in biopharma operations.

Whether you're in the early stages of development or scaling up for commercialization, understanding ADC manufacturing challenges is essential for bringing life-saving therapies to patients worldwide.

Find out how an autologous CAR-T platform is addressing challenges in cell therapy manufacturing. A three-day process shortens cycles, improves T-cell potency and durability, and reduces costs.